Proceedings of the 4th Green Development International Conference (GDIC 2022)

Cytopathological Overview of Cervical Smear in Maro Sebo Village, Jambi Provence, Indonesia

Authors
Fairuz1, *, S. S. Tasya2, D. Hasna1, A. U. Erisca1, M. Muthia3, Suhaili1
1Department of Histopathology, Faculty of Medicine and Health Sciences, Jambi University, Jambi, Indonesia
2Medical Students, Faculty of Medicine and Health Sciences, Jambi University, Jambi, Indonesia
3Department of Maternity Nursing, Faculty of Medicine and Health Sciences, University of Jambi, Jambi, Indonesia
*Corresponding author. Email: fairuz.quzwain@gmail.com
Corresponding Author
Fairuz
Available Online 7 November 2023.
DOI
10.2991/978-2-38476-110-4_98How to use a DOI?
Keywords
cervical pap; cytopathology; muaro sebo
Abstract

Cervical cancer is the second most common cancer and the highest cause of death in women in Indonesia. One of the checks that can be applied is the Pap smear. The purpose of this study was to examine the clinical and cytopathological features of cervical precancerous lesions according to the 2014 Bethesda classification. This study was a descriptive study with a cross-sectional approach. Data collection techniques using purposive techniques. The data used is primary data obtained in August 2022, with a sample of 27 patients and will be analyzed univariately. The most clinical characteristics of the patients were in the age group of 25–35 years, namely 11 patients (40.7%), 20 patients (74.0%) multiparous patients, 9 patients who did not use any contraception. Patients (33.4%), non-menopausal 21 patients (77.8%), 15 patients (55.5%) without complaints, 15 patients (55.5%) without findings, 1 patient (3.7%) with gynecological diseases, 27 patients (100%) patients without a risk relationship, 2 patients (7.4%) were smokers, the most menarche age was in the age group over 12 years, 15 patients (55.5%) and based on cytopathology results obtained 9 patients (33.4%) with NILM, 2 patients (7.4%) NILM-AS, 4 patients (14.8%) chronic cervicitis non-specific ASC-US, 11 patients (40.7%) with chronic cervicitis non-specific NILM, and 1 patient (3.7%) with NILM - Acute cervicitis. NILM non-specific chronic cervicitis was the most common cytopathological outcome, followed by NILM, ASC-US non-specific chronic cervicitis, NILM-AS, and NILM Acute Cervicitis.

Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

Volume Title
Proceedings of the 4th Green Development International Conference (GDIC 2022)
Series
Advances in Social Science, Education and Humanities Research
Publication Date
7 November 2023
ISBN
978-2-38476-110-4
ISSN
2352-5398
DOI
10.2991/978-2-38476-110-4_98How to use a DOI?
Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

TY  - CONF
AU  - Fairuz
AU  - S. S. Tasya
AU  - D. Hasna
AU  - A. U. Erisca
AU  - M. Muthia
AU  - Suhaili
PY  - 2023
DA  - 2023/11/07
TI  - Cytopathological Overview of Cervical Smear in Maro Sebo Village, Jambi Provence, Indonesia
BT  - Proceedings of the 4th Green Development International Conference (GDIC 2022)
PB  - Atlantis Press
SP  - 1023
EP  - 1032
SN  - 2352-5398
UR  - https://doi.org/10.2991/978-2-38476-110-4_98
DO  - 10.2991/978-2-38476-110-4_98
ID  - 2023
ER  -